carvedilol has been researched along with Angor Pectoris in 31 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol is a nonselective beta-blocker with alpha-mediated vasodilating properties that has been shown to be effective in systemic hypertension, stable angina, and congestive heart failure (CHF)." | 9.07 | Effects of carvedilol on ventricular arrhythmias. ( DasGupta, P; Lahiri, A; Müller-Beckmann, B; Senior, R; van der Does, R, 1992) |
| " Carvedilol low dose/high dose was shown to be at least as safe and well tolerated as metoprolol low dose/high dose both in younger and elderly patients." | 6.69 | Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. ( Griffiths, M; Hauf-Zachariou, U; Holtbrügge, W; König, S; Lahiri, A; Pfarr, E; van der Does, R, 1999) |
| "Carvedilol was well tolerated and produced significant hemodynamic improvement." | 5.27 | Effects of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina pectoris. ( Al-Khawaja, I; Lahiri, A; Raftery, EB; Rodrigues, EA, 1987) |
| "Carvedilol is a non-selective beta-adrenoceptor antagonist with vasodilating properties which has been shown to be effective in the management both of hypertension and of stable angina pectoris." | 5.08 | Vasodilating beta-blockers in heart failure. ( Raftery, EB, 1995) |
| "Carvedilol is a nonselective beta-blocker with alpha-mediated vasodilating properties that has been shown to be effective in systemic hypertension, stable angina, and congestive heart failure (CHF)." | 5.07 | Effects of carvedilol on ventricular arrhythmias. ( DasGupta, P; Lahiri, A; Müller-Beckmann, B; Senior, R; van der Does, R, 1992) |
| "In patients with chronic stable exertional angina pectoris, the antianginal and anti-ischemic efficacies and the safety of 25 mg carvedilol b." | 5.07 | Efficacy and safety of carvedilol in comparison with nifedipine sustained-release in chronic stable angina. ( Derr, I; Eberhardt, R; Ehmer, B; van der Does, R, 1992) |
| " Carvedilol, which is a nonselective beta-blocking and alpha 1-blocking drug, with additional Ca(2+)-antagonistic properties, is being developed as an antihypertensive, antianginal drug and as an adjunct therapy in congestive heart failure." | 4.78 | Development of a multiaction beta blocker. Scientific challenges and regulatory needs. ( Lessem, JN; Lukas, MA, 1993) |
| "Carvedilol--a vasodilating beta-blocker has been shown in multicentre trials to be as effective as standard beta-blockers in improving exercise tolerance in patients with angina pectoris and it is more effective than nifedipine." | 4.77 | Multiple action compounds in angina pectoris. ( Freedman, SB; Kelly, DT, 1989) |
| "Fatigue, but not breathlessness, remained a significant predictor for developing worsening heart failure (RR 1." | 2.71 | Symptoms in patients with heart failure are prognostic predictors: insights from COMET. ( Charlesworth, A; Cleland, JG; Ekman, I; Metra, M; Poole-Wilson, PA; Swedberg, K, 2005) |
| "Carvedilol is a nonselective beta-receptor antagonist with vasodilating properties primarily due to selective alpha-1 antagonism." | 2.69 | Effectiveness of three different doses of carvedilol for exertional angina. Carvedilol-Angina Study Group. ( Dennish, G; Ferry, D; Krug-Gourley, S; Lukas, MA; Pickering, E; Smith, LK; Weiss, R, 1998) |
| " Carvedilol low dose/high dose was shown to be at least as safe and well tolerated as metoprolol low dose/high dose both in younger and elderly patients." | 2.69 | Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. ( Griffiths, M; Hauf-Zachariou, U; Holtbrügge, W; König, S; Lahiri, A; Pfarr, E; van der Does, R, 1999) |
| "Carvedilol 25 mg b." | 2.67 | Treatment of chronic stable angina with carvedilol in comparison with nifedipine s.r. ( Derr, I; Eberhardt, R; Ehmer, B; Rudorf, J; Uberbacher, HJ; van der Does, R, 1991) |
| " Carvedilol appears to be effective in preventing or reducing effort angina due to reduced myocardial oxygen demand, and it exhibits an important dose-response effect." | 2.66 | Antianginal efficacy of carvedilol, a new beta-blocker with vasodilating action. ( Carter, G; Freedman, SB; Harris, PJ; Jamal, SM; Kelly, DT; Thomson, A, 1987) |
| "Carvedilol is a beta-adrenoceptor antagonist which also causes peripheral vasodilation primarily via alpha 1-adrenergic blockade." | 2.38 | Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. ( Campoli-Richards, D; McTavish, D; Sorkin, EM, 1993) |
| "Carvedilol was administered in increased every 4-week doses: 12." | 1.33 | Neutrophils superoxide anion generation during carvedilol therapy in patients with stable angina. ( Błaszczyk, J; Cegliński, T; Irzmański, R; Kowalczyk, E; Kowalska, E; Kowalski, J; Pawlicki, L; Petecka, E, 2005) |
| "Carvedilol is a novel non-selective beta-blocker without intrinsic sympathomimetic activity (ISA) and has vasodilating effect through blocking alpha 1 receptor." | 1.31 | [Effects of carvedilol on the hemodynamics and its tolerance in elderly patients]. ( Asai, T; Iguchi, A; Kanda, S; Koike, A; Kuzuya, M; Maeda, K, 2002) |
| "Carvedilol was well tolerated and produced significant hemodynamic improvement." | 1.27 | Effects of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina pectoris. ( Al-Khawaja, I; Lahiri, A; Raftery, EB; Rodrigues, EA, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (25.81) | 18.7374 |
| 1990's | 13 (41.94) | 18.2507 |
| 2000's | 9 (29.03) | 29.6817 |
| 2010's | 1 (3.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fi, Z | 1 |
| Szentes, V | 1 |
| Ekman, I | 1 |
| Cleland, JG | 1 |
| Swedberg, K | 1 |
| Charlesworth, A | 1 |
| Metra, M | 1 |
| Poole-Wilson, PA | 1 |
| Kowalski, J | 4 |
| Błaszczyk, J | 3 |
| Petecka, E | 1 |
| Irzmański, R | 4 |
| Kowalczyk, E | 1 |
| Kowalska, E | 1 |
| Cegliński, T | 3 |
| Pawlicki, L | 4 |
| Kowalski, M | 2 |
| Wróbel, W | 2 |
| Krzemińska, A | 1 |
| Krzemińiska, A | 1 |
| Banach, M | 1 |
| Barylski, M | 1 |
| McTavish, D | 1 |
| Campoli-Richards, D | 1 |
| Sorkin, EM | 1 |
| Lessem, JN | 1 |
| Lukas, MA | 2 |
| Raftery, EB | 5 |
| Hauf-Zachariou, U | 2 |
| Blackwood, RA | 1 |
| Gunawardena, KA | 1 |
| O'Donnell, JG | 1 |
| Garnham, S | 1 |
| Pfarr, E | 2 |
| Weiss, R | 1 |
| Ferry, D | 1 |
| Pickering, E | 1 |
| Smith, LK | 1 |
| Dennish, G | 1 |
| Krug-Gourley, S | 1 |
| Frishman, WH | 1 |
| van der Does, R | 6 |
| Holtbrügge, W | 1 |
| König, S | 1 |
| Griffiths, M | 1 |
| Lahiri, A | 5 |
| Martsevich, SIu | 1 |
| Koniakhina, IP | 1 |
| Alimova, EV | 1 |
| Kutishenko, NP | 1 |
| Lerman, OV | 1 |
| SoRelle, R | 1 |
| Vasil'ev, AP | 1 |
| Strel'tsova, NN | 1 |
| Gorbunova, TIu | 1 |
| Mal'tseva, IA | 1 |
| Zykova, EL | 1 |
| Asai, T | 1 |
| Kuzuya, M | 1 |
| Koike, A | 1 |
| Kanda, S | 1 |
| Maeda, K | 1 |
| Iguchi, A | 1 |
| Nahrendorf, W | 1 |
| Rading, A | 1 |
| Steinig, G | 1 |
| Schlote, A | 1 |
| Senior, R | 1 |
| Müller-Beckmann, B | 1 |
| DasGupta, P | 2 |
| Eberhardt, R | 2 |
| Derr, I | 2 |
| Ehmer, B | 2 |
| Kishida, H | 1 |
| Saito, T | 1 |
| Fukuma, N | 1 |
| Hata, N | 1 |
| Suzuki, T | 1 |
| Ohtsu, F | 1 |
| Rudorf, J | 1 |
| Uberbacher, HJ | 1 |
| Kaski, JC | 1 |
| Rodriguez-Plaza, L | 1 |
| Brown, J | 1 |
| Maseri, A | 1 |
| Jamal, SM | 2 |
| Freedman, SB | 3 |
| Thomson, A | 1 |
| Carter, G | 1 |
| Harris, PJ | 2 |
| Kelly, DT | 3 |
| Prichard, BN | 1 |
| Tomlinson, B | 1 |
| Rodrigues, EA | 3 |
| Jain, D | 1 |
| Hughes, LO | 1 |
| Kohli, RS | 1 |
| Whittington, JR | 1 |
| Al-Khawaja, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of a Mindfulness-Based Intervention on Symptoms and Signs, Well-Being and Health in Patients With Chronic Heart Failure[NCT04871178] | 50 participants (Actual) | Interventional | 2010-10-10 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for carvedilol and Angor Pectoris
| Article | Year |
|---|---|
[The benefits of carvedilol therapy in the treatment of patients with high cardiovascular risk].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Bisoprolol; Carbazoles; Cardi | 2016 |
Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Carbazoles; Carvedilol; Heart Failure; Hemody | 1993 |
Development of a multiaction beta blocker. Scientific challenges and regulatory needs.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 1993 |
Carvedilol.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; | 1998 |
Multiple action compounds in angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Carbazoles; Carvedilol; Humans; Propanolamines; Vasodi | 1989 |
Clinical pharmacology of multiple action compounds.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Carbazoles; Carvedilol; Humans; Propanolamine | 1989 |
19 trials available for carvedilol and Angor Pectoris
| Article | Year |
|---|---|
Symptoms in patients with heart failure are prognostic predictors: insights from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Carbazoles; Carvedilol; Disease Progression; Dou | 2005 |
[Effect of carvedilol on lipid peroxidation in patients with stable angina].
Topics: Adult; Angina Pectoris; Antihypertensive Agents; Carbazoles; Carvedilol; Dose-Response Relationship, | 2005 |
[Effect of carvedilol on antioxidative enzymatic defence in patients with stable angina].
Topics: Adult; Angina Pectoris; Antihypertensive Agents; Antioxidants; Carbazoles; Carvedilol; Catalase; Dos | 2005 |
Carvedilol modifies antioxidant status of patients with stable angina.
Topics: Adult; Angina Pectoris; Antioxidants; Carbazoles; Carvedilol; Catalase; Erythrocytes; Female; Glutat | 2008 |
Vasodilating beta-blockers in heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angina Pectoris; Carbazoles; Carvedilol; Dose-Res | 1995 |
The preventative effects of vasodilating beta-blockers in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Carbazoles; Carvedilol; Chronic Disease; Female; | 1996 |
Carvedilol versus verapamil in chronic stable angina: a multicentre trial.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Carbaz | 1997 |
Effectiveness of three different doses of carvedilol for exertional angina. Carvedilol-Angina Study Group.
Topics: Aged; Angina Pectoris; Carbazoles; Carvedilol; Cross-Over Studies; Double-Blind Method; Exercise Tes | 1998 |
Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Age Factors; Aged; Angina Pectoris; Antio | 1999 |
[Comparison of carvedilol and atenolol efficacy in patients with stable effort angina].
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Animals; Atenolol; Carbazoles; Carvedilol; Doubl | 2001 |
[Antioxidant and antiarrhythmic activity of carvedilol in patients with ischemic heart disease. Comparison with anaprilin].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Anti-Arrhythmia Agents; Antioxidants; Arrhythmias, Car | 2001 |
A comparison of carvedilol with a combination of propranolol and isosorbide dinitrate in the chronic treatment of stable angina.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Carbazoles; C | 1992 |
Effects of carvedilol on ventricular arrhythmias.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Carbazoles; Carv | 1992 |
Efficacy and safety of carvedilol in comparison with nifedipine sustained-release in chronic stable angina.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Antihypertensive Agents; Carbazoles; Carv | 1992 |
Treatment of chronic stable angina with carvedilol in comparison with nifedipine s.r.
Topics: Adult; Aged; Angina Pectoris; Carbazoles; Carvedilol; Chronic Disease; Delayed-Action Preparations; | 1991 |
Efficacy of carvedilol in exercise-induced myocardial ischemia.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Blood Pressure; Carbazoles; Carvedilol; C | 1987 |
Antianginal efficacy of carvedilol, a new beta-blocker with vasodilating action.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Blood Pressure; Carbazoles; Carvedilol; Dose-Response | 1987 |
Antianginal efficacy of carvedilol, a beta-blocking drug with vasodilating activity.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Blood Pressure; Carbazoles; Carvedilol; Clinical | 1986 |
Comparison of carvedilol and atenolol for angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Clin | 1987 |
6 other studies available for carvedilol and Angor Pectoris
| Article | Year |
|---|---|
Neutrophils superoxide anion generation during carvedilol therapy in patients with stable angina.
Topics: Adult; Angina Pectoris; Antihypertensive Agents; Carbazoles; Carvedilol; Case-Control Studies; Femal | 2005 |
50th Annual scientific sessions of the American college of cardiology.
Topics: Adrenergic alpha-Antagonists; Angina Pectoris; Carbazoles; Carvedilol; Fibroblast Growth Factor 2; G | 2001 |
[Effects of carvedilol on the hemodynamics and its tolerance in elderly patients].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Carb | 2002 |
Evaluation of a new vasodilating beta-blocking agent, carvedilol, in exertional angina using holter monitoring.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Carbazoles; Carvedilol; Drug Administration Sche | 1990 |
Effects of carvedilol in patients with impaired left ventricular function due to ischaemic heart disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Carbazoles; Carvedilol; Coronary Disease; Exercise Tes | 1989 |
Effects of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Blood Pressure; Carbazoles; Carvedilol; Electroc | 1987 |